🔬 Science
7h ago
Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer
Source ↗
👁 0
💬 0
Patients with estrogen receptor-positive (ER+), HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared with a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, were published today in the New England Journal of Medicine. Initial results of the evERA s
Comments (0)